People with T1D are at equal or higher risk for developing kidney disease compared to individuals with T2D. Diabetic kidney disease can lead to End Stage Renal Disease (ESRD) – and remains one of the highest causes of morbidity and mortality, severely reducing quality-of-life even in its mild to moderate forms in people with T1D. Researchers in Scotland led by Professor Touyz reported on specific mechanisms of oxidative stress underlying one of the most common causes of diabetic kidney disease. Prolonged oxidative stress triggers a series of biological events ultimately leading to many diabetic complications in multiple tissues and organs. Results from this study establishes a proof-of-concept approach to preventing kidney disease by reversing the effects of oxidative stress by inhibiting a component in the oxidative stress pathway using drug-like compounds. Most importantly, characterization of this elusive pathway and the potential of drug-like compounds to prevent diabetic kidney disease has translated into the initiation of a drug development program by at least one small pharmaceutical company. Clinical studies will be needed to demonstrate the potential value of such an approach to preventing diabetic kidney disease.
Ramifications for Individuals with T1D:
This research was conducted in an animal model of T2D in which their kidney disease closely resembles that in T1D animal models. This early stage approach to preventing kidney disease shows great promise for potentially reducing the occurrence of diabetic kidney disease.
Prof. Touyz’s research was funded from a JDRF grant with Dr. Mark Cooper as collaborator.
Investigators and Institutions:
Prof. Rhian M. Touyz, MBBCh, MSc(Med), PhD, is the recently appointed Director of the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland. She was the Canada Research Chair in Hypertension and Professor of Medicine at the Kidney Research Centre, Ottawa Hospital Research Institute (OHRI)/Univ of Ottawa. Prof. Touyz and colleagues conducted this study in Canada in collaboration with Dr. Mark Cooper at the Baker Research Institute in Australia.
Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM. 2013.
Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
Clin Sci (Lond). 2013 Feb 1;124(3):191-202.